TrialThe New England journal of medicine2016
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
5,761 papers cite itlatest 60 shown
this paperpooled ittrialcites it